SCHEMBL14947863

SCHEMBL14947863

CCCC[C@H](NC(=O)[C@@H](NC(=O)[C@]1(C)CCCc2cnnn2CCCC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)C(=O)[C@H](CCC(N)=O)NN1)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.40
MCL1 Q07820 3/20 0.40
PCSK9 Q8NBP7 1/20 0.39
MDM4 O15151 4/20 0.39
MDM2 Q00987 4/20 0.39
EIF4E P06730 2/20 0.39
EIF4EBP1 Q13541 2/20 0.39
KRAS P01116 2/20 0.39
TCF4 P15884 1/20 0.39
CTNNB1 P35222 1/20 0.39
ESR2 Q92731 3/20 0.38
EED O75530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14948248 1.00 ESR1 (0.40) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL16975610 0.90 MDM4 (0.43) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL14947855 0.89 MCL1 (0.47) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL14947860 0.88 MDM4 (0.43) ESR1MCL1MDM4MDM2EIF4E
SCHEMBL14950915 0.82 EIF4E (0.38) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL16975819 0.82 ESR1 (0.34) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL16975828 0.82 ESR1 (0.34) ESR1MCL1PCSK9MDM4MDM2
SCHEMBL12297508 0.76 MDM2 (0.58) ESR1PCSK9MDM4MDM2EIF4E
SCHEMBL12581072 0.71 MDM2 (0.68) PCSK9MDM4MDM2KRASEED
SCHEMBL14648779 0.68 MDM2 (0.52) ESR1PCSK9MDM4MDM2CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096684-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-08-04 US disclosed
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES GHRHR, GHSR, GHITM ESR1 470/4885MCL1 677/4885PCSK9 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.